目的 探討紅花注射液聯(lián)合西洛他唑片治療急性缺血性腦梗死的臨床療效。方法 選取2010年3月—2015年3月在中南大學(xué)湘雅醫(yī)院接受治療的急性缺血性腦梗死患者82例，根據(jù)治療方案的差別分為對(duì)照組和治療組，每組各41例。對(duì)照組口服西洛他唑片，100 mg/次，2次/d。治療組在對(duì)照組基礎(chǔ)上靜脈滴注紅花注射液，15 mL加入到10%葡萄糖注射液250 mL中，1次/d。兩組患者均治療2周。觀察兩組的臨床療效，比較兩組的血清學(xué)指標(biāo)和美國(guó)國(guó)立衛(wèi)生研究院卒中量表（NIHSS）評(píng)分。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為80.49%、97.56%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，兩組血清白細(xì)胞介素-6（IL-6）、血紅素氧合酶1（HO1）和N末端腦鈉肽原（NT-proBNP）水平明顯降低，而血管內(nèi)皮生長(zhǎng)因子（VEGF）、胰島素樣生長(zhǎng)因子-1（IGF-1）和轉(zhuǎn)化生長(zhǎng)因子-β₁（TGF-β₁）水平明顯增高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，兩組NIHSS評(píng)分均明顯下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）；且治療組NIHSS評(píng)分的下降程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。結(jié)論 紅花注射液聯(lián)合西洛他唑片治療急性缺血性腦梗死具有較好的臨床療效，可改善神經(jīng)功能，調(diào)節(jié)血清學(xué)指標(biāo)，安全性較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the clinical effect of Safflower Injection combined with Cilostazol Tablets in treatment of acute ischemic cerebral infarction. Methods Patients (82 cases) with acute ischemic cerebral infarction in Xiangya Hospital Central South University from March 2010 to March 2015 were enrolled in this study. According to the difference treatment plan, patients were divided into control and treatment groups, and each group had 41 cases. Patients in the control group were po administered with Cilostazol Tablets, 100 mg/time, twice daily. Patients in the treatment group were iv administered with Safflower Injection on the basis of the control group, 15 mL added into 10% glucose solution 250 mL, once daily. Patients in two groups were treated for two weeks. After treatment, the clinical efficacies were evaluated, and serological indexes and NIHSS scores in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.49% and 97.56%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of IL-6, HO1, and NT-proBNP in two groups were significantly decreased, but the levels of VEGF, IGF-1, and TGF-β₁ in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the NIHSS scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the NIHSS score in the treatment group were significantly lower than that in the control group, with significant difference between two groups (P < 0.05). Conclusion Safflower Injection combined with Cilostazol Tablets has clinical curative effect in treatment of acute ischemic cerebral infarction, can improve nerve function, and regulate serological indexes, with good safety, which has a certain clinical application value.